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Schizophrenia is a severe psychiatric disorder with strong heritability and marked heterogeneity in symptoms, course, and treatment
response. There is strong interest in identifying genetic risk factors that can help to elucidate the pathophysiology and that might result
in the development of improved treatments. Linkage and genome-wide association studies (GWASs) suggest that the genetic basis of
schizophrenia is heterogeneous. However, it remains unclear whether the underlying genetic variants are mostly moderately rare and
can be identified by the genotyping of variants observed in sequenced cases in large follow-up cohorts or whether they will typically
be much rarer and therefore more effectively identified by gene-based methods that seek to combine candidate variants. Here, we
consider 166 persons who have schizophrenia or schizoaffective disorder and who have had either their genomes or their exomes
sequenced to high coverage. From these data, we selected 5,155 variants that were further evaluated in an independent cohort of
2,617 cases and 1,800 controls. No single variant showed a study-wide significant association in the initial or follow-up cohorts.
However, we identified a number of case-specific variants, some of which might be real risk factors for schizophrenia, and these can
be readily interrogated in other data sets. Our results indicate that schizophrenia risk is unlikely to be predominantly influenced by
variants just outside the range detectable by GWASs. Rather, multiple rarer genetic variants must contribute substantially to the predis-
position to schizophrenia, suggesting that both very large sample sizes and gene-based association tests will be required for securely
identifying genetic risk factors.Introduction
Schizophrenia (MIM 181500) is characterized by positive
symptoms (e.g., delusions, hallucinations, and disorga-
nized thinking), negative symptoms (e.g., flat affect, loss
of spontaneity, diminished initiative and capacity for
pleasure, and impaired volition), numerous cognitive
dysfunctions of varying severity, mood disturbances, and
suicidality. Antipsychotic drugs are usually effective in
treating positive symptoms, and to a much lesser extent,
cognitive impairment. Clozapine, the prototypical atypical
antipsychotic drug, has also been shown to uniquely
reduce the risk of suicide in schizophrenic individuals.1,2
Cognitive impairment is considered the major cause of
functioning deficits,3 but the other components of the
illness contribute as well by collectively interfering
substantially with the quality of life and constituting
significant burdens on the families of individuals with
schizophrenia. Genetic studies that implicate variants in
specific genes as risk factors for the syndrome might help1Center for Human Genome Variation, Duke University School of Medicine
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the identification of novel treatment targets.
Despite many years of study, the genetic basis of schizo-
phrenia remains largely unknown. Many complex
diseases, including neuropsychiatric disorders such as
epilepsy and Alzheimer disease (MIM 104300),4,5 have
been shown to have Mendelian forms; however, no single
gene mutations of large effect have been conclusively
identified in schizophrenia. Moreover, genome-wide asso-
ciation studies (GWASs) have identified only variants asso-
ciated with extremely small effects on risk. For example,
GWAS meta-analyses on 8,000 cases and 19,000 controls
identified several high-frequency associations with very
small odd ratios (1.1–1.3), effectively ruling out the possi-
bility that risk of schizophrenia is determined primarily
by a modest number of common variants (or even
hundreds of common variants).6–8 On the other hand,
studies of rare copy-number variants (CNVs) have shown
that a modest proportion of schizophrenia cases can be
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with high but incomplete penetrance (the estimated odds
ratios range from 2.7 to 25).9–12 Because of their rarity and
the multiple genes involved in many of the CNV regions,
these CNVs represent daunting targets for drug develop-
ment unless they lead to more generalized downstream
effects that affect a much higher percentage of people
with schizophrenia.
Given that very little of the heritability of schizophrenia
is explained by nongenetic causes and that there is good
evidence for a role for rare variants, there is intense interest
in using next-generation sequencing (NGS) for the identi-
fication of additional rare variants associated with schizo-
phrenia. These, in turn, might help researchers identify
pathways that could inform and motivate novel drug-
development efforts. Two recent studies explored the role
of highly penetrant individual sequence variants in schizo-
phrenia by examining the number and function of de
novo variants in apparent sporadic schizophrenia (in 14
and 53 cases, respectively).13,14 The authors of both studies
concluded that an excess of de novo variants was seen in
the schizophrenia cases and, additionally, that more of
these than expected were damaging, suggesting that at
least some schizophrenia cases are caused by highly pene-
trant de novo variants. However, the high heritability of
schizophrenia is not compatible with the hypothesis that
most cases are the result of de novo mutations.
The genetic explanation of themajority of schizophrenia
cases therefore remains unresolved. One possibility not
excluded by current evidence is that variants only slightly
below the detection threshold for GWASs have appreciable
effects on risk (for example, variants with frequencies
approaching 0.5% and relative risks of 2 or slightly more).
If there were many such variants, some could be readily
detected by the sequencing of case genomes and the
genotyping of identified variants in a large cohort of
additional cases. This is the design we follow here. Another
possibility is that most pathogenic mutations have fre-
quencies well below the GWAS detection threshold. For
such variants, the most efficient design will be to employ
screens on the basis of the combination of variants across
particular genes or regions. There is a clear analogy here
with CNVs. Although each individual mutation in a
schizophrenia-associated CNV region appears to have
arisen either de novo or very recently and thus has an
extremely low frequency, they collectively reach frequen-
cies that are significantly different in cases than in con-
trols.9,10,15–19 Whether this will be the requisite paradigm
for identifying sequence variants remains to be resolved.
Here, we examined the first possibility—whether
a substantial proportion of schizophrenia cases can be ex-
plained by individual, moderately rare variants with strong
effects. We took a set of 5,155 rare variants identified in
166 sequenced schizophrenia genomes and exomes, and
we genotyped them in an additional unrelated 2,617 cases
and 1,800 controls to determine whether rare variants
overrepresented in unrelated cases relative to controls
could be detected in samples of this size.304 The American Journal of Human Genetics 91, 303–312, August 1Subjects and Methods
Study Participants
Discovery cases were 166 individuals with a diagnosis of schizo-
phrenia or schizoaffective disorder and included treatment-resis-
tant cases and/or cases with a strong family history. The original
sequenced cases comprised 47 Finnish schizophrenic individuals
defined as resistant to treatment (i.e., they qualified for treatment
with clozapine), 87 United States individuals with treatment-
resistant schizophrenia or schizoaffective disorder (all were
whole-exome sequenced), and 32 United States individuals with
a diagnosis of schizophrenia and a family history of schizophrenia
or other severe neuropsychiatric disorders (these individuals were
whole-genome sequenced). The sample was approximately 10%
African ancestry, 89% European ancestry, and 1% other (Native
American or Hispanic). The institutional review boards (IRBs) of
Duke University Medical Center and collaborating institutions
approved all procedures. Follow-up cases (n ¼ 2,756) were
544 United States individuals with a family history of schizo-
phrenia or other severe neuropsychiatric disorders (20 of these
individuals overlapped with the whole-genome-sequenced
subjects for quality-control purposes), 364 United States samples
including 168 treatment-resistant individuals (79 overlapped
with the exome-sequenced individuals), 360 Italian samples, and
1,567 samples obtained from the Rutgers repository. Follow-up
cases were 45% African ancestry, 54% European ancestry, and
1% other (Hispanic, Asian, or Middle Eastern). Informed consent
was obtained from all participants or their legal guardians.
Discovery controls (n ¼ 307) and follow-up controls (n ¼ 1,932,
including 65 discovery controls for quality-control purposes)
either were subjects who were not enriched for (but not specifi-
cally screened for) neuropsychiatric disorders, who were enrolled
in Duke IRB-approved protocols, and who consented to future
unrelated research or were samples received from outside institu-
tions under a Duke IRB exemption. Discovery controls were 6%
African ancestry, 92% European ancestry, and 2% other (Hispanic,
Native American, orMiddle Eastern). Follow-up controls were 37%
African ancestry, 59% European ancestry, and 3% other (Hispanic,
Asian, or Middle Eastern).
Power calculations were performedwith Power for Genetic Asso-
ciation Analyses.20Targeted Capture and Exome andGenome Sequencing
For whole-exome sequencing, the target regions were captured
with the Agilent SureSelect Human All Exon 37 Mb or 50 Mb Kit
(Agilent Technologies, Santa Clara, CA) according to the vendor-
provided protocols. Sequencing was performed in the Center for
Human Genome Variation Genomic Analysis Facility with either
Illumina GAII or HiSeq machines. Whole-genome sequencing
was performed as previously described.21 Each read was then
aligned to the reference genome (National Center for Biotech-
nology Information human genome assembly build 36; Ensembl
core database release 50_36l 1) with the Burrows-Wheeler Align-
ment tool,22 and single-nucleotide variants (SNVs) and small
indels were identified with SAMtools.23 PCR duplicates were
removed with Picard software (see Web Resources).Variant Selection
We focused on variants annotated as functional, which was
defined as nonsynonymous, nonsense, or located in the canonical
splice sites. The analysis was restricted to variants with a minor0, 2012
Figure 1. Range of Relative Risks and MAFs that Are Detectable
with 99% Power at p< 0.05 and, after Correction for All Included
Variants, p < 1.5 3 107 in a Cohort of 166 Cases and 307
Controlsallele frequency (MAF) < 0.05 or, for the recessive model, a MAF <
0.3. For each variant tested, only individuals with a minimum
coverage of 103 at that site were included (n ¼ 152,511 SNVs
for the allelic model and 172,886 for the recessive model).
We first tested for genetic association by using Association Tests
for Annotated Variants (ATAV [see Web Resources]) to run Fisher’s
exact tests comparing exome-captured regions from cases and
controls. We then removed variants that had greater than 50%
of the individuals missing as a result of low coverage, variants
with a Hardy-Weinberg equilibrium p value < 0.001, variants
with a p value < 0.05 but whose frequency was higher in controls,
and variants that were clearly driven by differences between the
Finnish or African American subjects and the other samples. All
other associated (p < 0.05) variants were put forward for scoring
in the iSelect follow up (n ¼ 316 allelic, n ¼ 206 recessive).
Because of an expectation of high locus heterogeneity, we recog-
nized that a gene might play a role in only a single case in our
sequenced samples, and so we also selected variants that formed
genotypes that were present in cases but not in controls. From
this set, we removed the following: variants that were present in
only one individual (‘‘unique variants’’) if that individual had
greater than the mean þ 1 standard deviation of unique variants
(because thesemight have been poor-quality calls) (n¼ 485 allelic,
n ¼ 5 recessive), unique variants that were present only in the
Finnish samples (because we had no Finnish controls) (n ¼ 293
allelic, 12 recessive), and unique variants in a low-coverage sample
(23.5–253; n ¼ 4 samples; n ¼ 33 allelic, n ¼ 1 recessive).
We then included for scoring (1) all variants that were in an
essential splice site, destroyed a stop codon, or introduced a new
stop codon (n ¼ 1,643 allelic, n ¼ 43 recessive); (2) all variants
in a region associated with epilepsy, schizophrenia, autism, or
intellectual disability through rare CNVs (n ¼ 863 allelic, 2 reces-
sive), and (3) all nonsynonymous variants that got a PolyPhen224
rating of ‘‘probably damaging’’ (n¼ 3,736 allelic, n¼ 51 recessive).
These 6,860 variants were submitted to Illumina’s online Assay
Design Tool for the prediction of the likelihood of a successful
assay. All variants with a score below 0.6 were removed, leaving
5,788 variants.iSelect Quality Control
The raw data (idats) from the custom iSelect genotyping were
brought into the Illumina GenomeStudio software. All variantsThe Americwere clustered with the GenomeStudio default parameters. The
call rates were inspected, and any samples with a call rate below
0.95 were removed from analysis. Each variant call was manually
inspected for clustering accuracy, and any obvious miscalls were
corrected or deleted if correcting was not possible because of irreg-
ular clustering. Genders were checked on the basis of X and Y chro-
mosome variants, and mismatched samples were excluded. For
a subset of samples, we also had Illumina genome-wide SNP array
data, which we used to check the concordance for overlapping
SNPs, and discordant samples were excluded from analysis. Of
these 5,788 variants, 5,155 variants were successfully genotyped
and passed all quality-control checks. We obtained genotypes for
these variants in an additional 2,617 cases and 1,800 controls
that passed all quality-control checks. Individuals with epilepsy
were also genotyped with the iSelect array, and all putative schizo-
phrenia-associated variants were investigated in cases with
epilepsy for the evaluation of possible variable expressivity.25Data Analysis
Because of allele-frequency differences between subjects of African
and European descent, we analyzed these two population groups
separately and then, where appropriate, combined the p values
by using a Fisher’s trend test. Fisher’s allelic and recessive tests
were performed with PLINK (see Web Resources). According to
PLINK defaults, only females were included in the Fisher’s exact
test for X chromosome variants.Comparison of Validation Rates
To determine whether there were differences between the valida-
tion rates among different classes of functional variants, we took
all autosomal variants that were seen in only a single sample in
the initial sequencing cohort. These were considered to be the
most vulnerable calls. We then selected from this group only the
variants that were present in an individual who was genotyped
with the iSelect array, and we determined for each variant whether
it had also been identified by the iSelect genotyping. Those iden-
tified were classed as validated, and we compared the percentage
of validated variants among different functional groups.Results
Association Testing
We performed whole-exome (n ¼ 134) or whole-genome
sequencing (n ¼ 32) on 166 schizophrenia cases and 307
controls (n ¼ 256 for exome sequencing, and n ¼ 51 for
genome sequencing) and followed this with Fisher’s Exact
test to look for association with schizophrenia by using
both an allelic and a recessive model after excluding
common variants. This resulted in a total of 337,312 vari-
ants, for which Bonferroni correction for multiple testing
required a p value < 1.5 3 107. At this p value threshold
in a data set of this size (and with a focus exclusively on
rare variants), we would have limited power to detect
anything but variants with an extremely high relative
risk (Figure 1). As expected, no variant achieved the
required level of significance in the initial sequence data.
This is not surprising because variants that would show
significance in this initial sequence data set would havean Journal of Human Genetics 91, 303–312, August 10, 2012 305
Table 1. Summary of Outcomes for Variants by Original Inclusion Criteria
Reason for Original Inclusion (n ¼ 5,788)
Failed or
Excluded
Present in Controls, p < 0.05 Absent in Controls
In African
Americans
Only
In European
Ancestry
Only
In Both
Ancestral
Groups
In Neither
Ancestral
Group
In 0
Additional
Cases
In 1
Additional
Case
In > 1
Additional
Case
p < 0.05 (n ¼ 428) allelic (n ¼ 242) 30 3 28 2 173 4 2 0
recessive (n ¼ 186)a 37 5 11 1 131 1 0 0
In > 1 case and 0
controls (n ¼ 861)
allelic (n ¼ 843) 94 9 15 0 476 192 34 23
recessive (n ¼ 18)a 2 0 1 0 12 2 1 0
In 1 case and 0
controls
(n ¼ 4,498)
allelic (n ¼ 4,280) 434 28 9 0 1,443 1,929 301 136
recessive (n ¼ 218)a 36 2 3 0 103 60 7 7
ap values are given for recessive tests; counts are for homozygous genotypes.effect sizes that would be expected to have been identified
in linkage analyses.
If we use a cutoff of p < 0.05 instead, however, we are
powered to identify variants over a much broader range of
effect sizes and allele frequencies (Figure 1), although the
majority of these variants will be false positives. We there-
fore adopted a two-stage strategy in which (1) we used the
discovery cohort to identify a variant set that was likely to
be enriched with schizophrenia-associated variants (those
with p < 0.05 and selected as described in the Subjects
and Methods section; n ¼ 428) and (2) we used a follow-
up sample of 2,617 cases and 1,800 controls to look for
corroborating evidence of association. We combined the
original sequencing data with the iSelect data to produce
a final data set of 2,785 cases and 2,120 controls.
Because we didn’t have enough markers to accurately
adjust for population stratification, we performed Fisher’s
exact tests (for both recessive and allelic models) on indi-
viduals of African and European descent separately, and
we used a logistic regression with self-described race
(including only subjects of European or African ancestry)
to look for variants that associated in both ancestral groups.
After a Bonferroni correction for all original 337,312
variants, p< 1.53 107 was required for study-wide signif-
icance. The lowest p values in the combined data set were
0.0003 (allelic) and 0.01 (recessive). The most significantly
associated variants in the African-American-only analysis
had p values of 0.0006 (allelic) and 0.0005 (recessive),
and the most significant variants in Europeans were
5.9 3 106 (allelic) and 0.01 (recessive). The most strongly
associated variant was a nonsynonymous AL589787.16
variant (Human Genome Organization [HUGO]: N/A;
rs7098669), which was originally included because it
showed association in the recessive model. This variant
shows substantial variation in allele frequency across pop-
ulations, and the association probably reflects population
stratification. It is interesting to note, however, that this
SNP lies within an open reading frame (C10orf90) found
to contain two independent schizophrenia associations
in the recent mega-GWAS, although the association did
not hold up in the follow-up cohort of that study.26306 The American Journal of Human Genetics 91, 303–312, August 1Evaluation of Genotypes Exclusive to Cases
Most very rare highly penetrant schizophrenia-associated
genotypes would not be expected to show a significant
association in a data set of the size of our discovery cohort.
Such genotypes would be found exclusively in cases but
only in very small numbers. We therefore also followed
up all genotypes that were present in two cases and no
controls (n ¼ 861) and a subset of those present in one
case and no controls (n ¼ 4,498; see Subjects and Methods
for selection criteria) because this data set is likely to be
enriched with very rare variants with high penetrance.
Table 1 summarizes the iSelect outcome for the different
categories of variants. Of the 4,028 genotypes originally
present in only a single case and successfully genotyped
in the follow up, 1,588 (39%) were seen in an iSelect
control and 1,989 (49%) were seen in only one or no
further cases. To further explore the frequency of these
variants in controls, we referred to the Exome Variant
Server (National Heart, Lung, and Blood Institute [NHLBI]
Exome Sequencing Project, Seattle, WA). Tables S1 and S2,
available online, show all case-specific variants and case-
specific homozygotes, respectively.
Some variants remained absent in all controls and
were found to be present in several additional cases (Table
2). The variant present in the most cases (n ¼ 5) is a
nonsynonymous mutation (g.1882C>T [Arg628Cys];
ENST00000380099) in KL (MIM 604824), a gene that acts
mainly in the renal and cardiovascular systems.27
However, KL has also been implicated in the regulation
of vitamin D metabolism. Klotho-deficient mice, for
example, show degeneration of mesencephalic dopamine
neurons28 and other aging phenotypes, such as hearing
loss,29 which can be rescued with a vitamin-D-deficient
diet. Although KL has not been previously associated
with schizophrenia to our knowledge, substantial evidence
implicates alterations in vitamin D levels, especially defi-
ciency, as a schizophrenia risk factor that might also help
to explain certain epidemiological findings, such as season
of birth and latitude-gradient effects on geographic differ-
ences in incidence and prevalence.30–32 In addition,
prenatal vitamin D deficiency has been shown to cause0, 2012
Table 2. SNVs that Were Seen in Two or More Follow-Up Schizophrenia Cases and that Were Absent in All Study Controls and Also In ariant in the NHLBI Exome-Sequenced Cohort
Variant (chr_
hg18 position_
variant allele)a Gene
MIM
Number
Transcript
(Ensembl 50_36l) RefSeq mRNA
Position of Sequence
and Amino Acid Change
Annotated
Function
Total
Cases
European
American
Case
Counts
(Hom/
Het/Ref)
European
American
Control
Counts
(Hom/
Het/Ref)
African
America
Case
Counts
(Hom/
Het/Ref)
African
American
Control
Counts
(Hom/
Het/Ref)
Other
Case
Counts
(Hom/
Het/Ref)
Other
Control
Counts
(Hom/
Het/Ref)
Total
Samples
(NHLBI
Cohort)
European
American
Samples
(NHLBI
Cohort)
African
American
Samples
(NHLBI
Cohort)
13_32533098_T KL 604824 ENST00000380099 NM_004795.3 c.1882C>T (p.Arg628Cys) NS 5 0/1/1,564 0/0/1,359 0/4/1,186 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
19_2785443_A ZNF554 NA ENST00000317243 NM_001102651.1 c.1210G>A (p.Gly404Arg) NS 4 0/3/1,561 0/0/1,359 0/1/1,189 0/0/679 0/0/30 0/0/82 5,351 3,508 1,843
20_34245584_G EPB41L1 602879 ENST00000344237  c.59A>G (p.His20Arg) NS 4 0/4/1,560 0/0/1,359 0/0/1,187 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
2_238150673_A RAB17 602206 ENST00000264601 NM_022449.3 c.401C>T (p.Thr134Met) NS 4 0/0/1,565 0/0/1,359 0/4/1,186 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
21_44639800_T TRPM2 603749 ENST00000397928 NM_003307.3 c.1870G>T (p.Asp624Tyr) NS 4 0/3/1,561 0/0/1,359 0/1/1,189 0/0/679 0/0/30 0/0/82 5,376 3,508 1,868
1_55290595_T PCSK9 607786 ENST00000302118 NM_174936.3 c.580C>T (p.Arg194Trp) NS 3 0/0/1,565 0/0/1,358 0/3/1,187 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
11_111555378_T BCDO2 611740 ENST00000393032 NM_001037290.2 c.154C>T (p.Arg52*) X 3 0/3/1,562 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
11_35290538_T SLC1A2 600300 ENST00000395750 NM_001195728.2 c.317G>A (p.Arg106His) NS 3 0/2/1,563 0/0/1,359 0/1/1,189 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
12_12952740_A GPRC5A 604138 ENST00000014914 NM_003979.3 c.290G>A (p.Arg97His) NS 3 0/0/1,565 0/0/1,359 0/3/1,187 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
15_41875227_T SERINC4 614550 ENST00000299969  c.918-1C>T splice 3 0/3/1,562 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
16_1083724_C C1QTNF8 614147 ENST00000328449 NM_207419.3 c.537C>G (p.Tyr179*) X 3 0/3/1,557 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 5,368 3,500 1,868
16_30958421_A STX4 186591 ENST00000313843 NM_004604.3 c.761G>A (p.Arg254His) NS 3 0/1/1,564 0/0/1,359 0/2/1,188 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
16_69543869_T HYDIN 610812 ENST00000316490  c.6340G>A (p.Gly2114Arg) NS 3 0/3/1,562 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 4,650 3,215 1,435
17_7769756_A KCNAB3 604111 ENST00000303790 NM_004732.3 c.508C>T (p.Arg170*) X 3 0/3/1,562 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
19_19506937_A AC011448.5 NA ENST00000397179 NM_198537.3 c.413G>A (p.Arg138Gln) NS 3 0/3/1,562 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 5,167 3,422 1,745
19_60041100_T KIR3DL3 610095 ENST00000391729  c.328C>T (p.Gln110*) X 3 0/0/1,559 0/0/1,355 0/3/1,186 0/0/679 0/0/30 0/0/82 5,264 3,418 1,846
2_32578230_C BIRC6 605638 ENST00000261359  c.8497G>C (p.Glu2833Gln) NS 3 0/0/1,542 0/0/1,337 0/3/1,187 0/0/679 0/0/29 0/0/75 5,379 3,510 1,869
3_114481460_A BOC 608708 ENST00000355385 NM_033254.2 c.2120G>A (p.Arg707His) NS 3 0/2/1,563 0/0/1,359 0/0/1,190 0/0/679 0/1/29 0/0/82 5,379 3,510 1,869
3_42714733_A HHATL 614071 ENST00000341477  c.325C>T (p.Arg109Cys) NS 3 0/1/1,564 0/0/1,359 0/0/1,190 0/0/679 0/2/28 0/0/82 5,379 3,510 1,869
6_117745049_A ROS1 165020 ENST00000368507  c.6067A>T (p.Met2023Leu) NS 3 0/0/1,565 0/0/1,359 0/3/1,187 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
7_65077123_A GUSB 611499 ENST00000345660  c.916C>T (p.Arg305*) X 3 0/3/1,562 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
7_82419591_T PCLO 604918 ENST00000333891  c.8407G>A (p.Val2803Ile) NS 3 0/0/1,512 0/0/1,312 0/3/1,186 0/0/679 0/0/29 0/0/80 5,032 3,389 1,643
7_86891201_A ABCB4 171060 ENST00000394680  c.2168G>T (p.Gly723Val) NS 3 0/0/1,565 0/0/1,359 0/3/1,187 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
7_88803894_A ZNF804B NA ENST00000333190 NM_181646.2 c.3662C>A (p.Ala1221Asp) NS 3 0/3/1,562 0/0/1,359 0/0/1,190 0/0/679 0/0/30 0/0/82 5,379 3,510 1,869
A full list of variants, including those that were absent in our study but that were either seen in NHLBI controls or not covered in the NHLBI exome-sequence cohort, can be seen in Table S1. The following abbreviations are
used: NS, nonsynonymous; X, nonsense; and NA, not available.
aNo variant had an rs number.
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lasting changes in NMDA-mediated brain function in
adult rats.33 Other genes of interest with case-only vari-
ants include EPB41L1 (MIM 602879), SLC1A2 (MIM
600300), STX4 (MIM 186591), HYDIN (MIM 610812),
PCLO (MIM 604918), and ZNF804B. EPB41L1 encodes
the erythrocyte membrane protein band 4.1-like N,34
which colocalizes with AMPA receptors at excitatory
synapses and is thought to mediate the interaction of
the AMPA receptors with the cytoskeleton.35 It has also
been shown to be necessary for the formation of calcium
waves in the mediation of neurite formation.36 A recent
study of synaptic protein sequencing reported a de novo
functional missense mutation in EPB41L1 in nonsyn-
dromic intellectual disability.37 SLC1A2 (aka, EAAT2 and
GLT1) encodes a glial high-affinity glutamate transporter
and is themajor transporter in the forebrain.38Mice lacking
Slc1a2 have spontaneous lethal seizures and are vulnerable
to glutamate neurotoxicity after forebrain trauma.39 STX4
directs membrane fusion at excitatory glutamatergic syn-
apses and is essential for normal dendritic spine mor-
phology, retrograde synaptic signaling, and long-term
potentiation at hippocampal synapses.40 A frameshift
mutation in Hydin causes recessively transmitted hydro-
cephalus in the mouse.41 Additionally, a paralog of HYDIN
is included in 1q21.1 microdeletions and microduplica-
tions, which have been associated with microcephaly,
macrocephaly, and neuropsychiatric disorders, including
schizophrenia.16 PCLO encodes Picollo, which acts along-
side Bassoon, Syntaxin, SNAP-25, and N-Cadherin in the
presynaptic active zone, a specialized regionwhere synaptic
vesicles dock and fuse.42 Piccolo is upregulated in the
nucleus accumbens in response to methamphetamine,
and antisense suppression of Piccolo increases the behav-
ioral response to amphetamine and causes synaptic accu-
mulation of dopamine.43 ZNF804B is a paralog of ZNF804A
(MIM 612282), which has shown to be associated with
schizophrenia in GWASs.44 Some variants were present in
both cases and controls but were homozygous only in cases
(see Table S2). Two variants were homozygous in three or
more cases and absent in all controls, but they were both
predicted to be benign.
Interestingly, it was recently shown that loss-of-function
mutations have a lower validation rate than other classes
of variants.45 This is expected because deleterious variants
are likely to be less common than those with moderate or
no function, and thus, all else being equal, there is a lower
prior that deleterious variants are real. We searched for
a similar effect in our data, although we expected our vali-
dation rate in general to be higher because (1) we required
high stringency for variants to be carried to follow up and
(2) we looked almost exclusively at rare variants predicted
to have strong functional effects, so the magnitude of the
difference among them would be expected to be reduced.
Nevertheless, we do see an attenuated effect as described
by MacArthur et al.,45 such that if we compare validation
rates (as defined by a variant being observed on the
iSelect array) among types of variants, the rates for very308 The American Journal of Human Genetics 91, 303–312, August 1rare nonsense (76%, n ¼ 388) and essential splice variants
(73%, n ¼ 221) are lower than those for nonsynonymous
variants (86%, n ¼ 2826).
Discussion
In this large-scale report of sequenced schizophrenia
genomes, we have looked for evidence of association of
individual, rare, highly penetrant sequence variants in
a discovery cohort of 166 cases and 307 controls and in
a follow-up cohort of 2,756 cases and 1,932 controls. We
found no significantly associated variants after Bonferroni
correction for multiple hypothesis testing.
Having found no significantly associated SNVs, we
focused on variants that were present in more than one
case and absent in controls. At least some of these might
ultimately prove to be statistically associated with schizo-
phrenia, even though each was individually too rare to
reach study-wide significance in this data set. We found
a small number of variants that remain good candidates
as individual schizophrenia-associated variants and that
are high priority for follow-up studies. However, because
of the low frequency of these variants, large collaborative
studies will be required for providing statistically signifi-
cant evidence for their association with schizophrenia.
As an illustrative example, we can consider the top hit,
amissense KLmutation that was present in 5 of 2,780 cases
and absent in 7,417 controls. Assuming that the frequency
in cases remains at 0.18% and that we have equal numbers
of cases and controls, we would need to see about 23 more
schizophrenia cases with this variant, which would require
approximately 13,000 schizophrenia cases and controls
for this individual variant to obtain study-wide signifi-
cance (p < 1.5 3 107).
This study had 99% power to detect moderately rare
(1%–5%) variants with relative risks between 2 and 6.
Because some variants in this frequency range would be
poorly represented on GWAS chips46 and because consis-
tently detecting effect sizes in part of this range would be
difficult with linkage studies,47 variants with these proper-
ties have not previously been systematically investigated
on a genome-wide scale in relation to schizophrenia. On
the basis of our findings and those of previous studies,
some possible genetic architectures for schizophrenia risk
appear increasingly unlikely and include (1) a small
number of highly penetrant loci explaining the majority
of cases (linkage studies), (2) a moderate number (less
than several hundred) of common variants with low rela-
tive risks underlying most cases (GWASs), and (3) so-called
‘‘goldilocks alleles,’’48 or moderately rare variants that have
moderate relative risks and that explain most cases
(present study). This finding suggests that the majority of
schizophrenia-associated variants will be of very low
frequency and that their association with schizophrenia
will most readily be confirmed by their collective presence
in genes associated with schizophrenia with the use of
collapsing methods and related approaches49–52 rather0, 2012
than with variant-specific frequency differences between
cases and controls.
These findings have a number of implications. First, one
outcome of the 1000 Genomes Project is novel GWAS
arrays that extend to variants in the 1%–5% frequency
range. Our results suggest that the use of these arrays in
relation to schizophrenia is unlikely to reveal significant
associations for relative risks above 2.
Second, our data strongly suggest that genetic risk
factors for schizophrenia are outside the range of what is
easily detected in sample sizes of the sort used here. For
example, although our power to detect variants with
frequencies below 1% is low, we should have detected
some of them if there were many risk factors with modest
effect sizes near this frequency cutoff. Thus, at least in
terms of the relatively rare and high impact variants
contributing to schizophrenia risk, the genetic architecture
is one characterized by high locus heterogeneity, high
allelic heterogeneity, or, more likely, both. Beyond locus
and allelic heterogeneity, the results could also be consis-
tent with oligogenic, polygenic, or epistatic models in
which effect sizes for individual variants are very modest
and the genotypes are reasonably penetrant only in combi-
nation.We did not explicitly test for suchmodels given the
current sample sizes. Considering the number of tests
required for open-ended screens of interacting variants
(even those limited to interacting pairs and restricting
analyses to common variants), we suspect that such inter-
actions will need to be identified secondarily to the identi-
fication of a main effect, however small, for a single variant
or through testing of specific hypotheses analyzing small
sets of variants in defined biological pathways.
It is valuable to consider these observations in light of
the example of CNVs. CNVs were the first type of rare
variants that could be detected on a genome-wide scale.
When all similar (but not necessarily identical by descent)
CNVs in a region were considered together, moderately
rare CNVs with relative risks from 2 to 25 were immedi-
ately and definitively associated with schizophrenia risk
across different cohorts and populations.9,10,17 Because
other types of rare genetic variation, such as SNVs and in-
dels, were not available for comparison, it was not possible
to determine whether these properties were specific to
large structural variants or were representative of rare
schizophrenia-associated variants in general. Here, we
were able to systematically search for associated SNVs
that have similar relative risks and that explain as high
a proportion of cases as some of the CNV regions, and we
failed to identify any.
It is essential to appreciate that the schizophrenia-associ-
ated CNVs were detectable because recurrent mutation
greatly increases the number of affected cases. Any given
mutation event leading to a CNVappears to be responsible
only for a few cases among closely related individuals.10 If
SNVs prove analogous, we would expect certain individual
genes or gene pathways to associate with schizophrenia,
although individual variants in those genes would not beThe Americfrequent enough to reach statistical significance by them-
selves in the sample sizes used in our follow-up genotyping
experiment. The clear implication is that collapsing
methods that combine qualifying variants in individual
genes and/or much larger sample sizes will be required
for finding secure evidence of risk-conferring genes. Such
a conclusion should not necessarily discourage the pros-
pects for gene discovery in schizophrenia; rather, it
suggests that the clearest path to discovery should focus
on both significantly expanded samples sizes and sophisti-
cated methods for appropriately combining qualifying
variants affecting the same genes.49–52 Thus, we propose
two possible strategies: one that sequences a sufficiently
large discovery cohort to prioritize genes in terms of their
load of qualifying mutations and that further sequences
those genes of interest in additional samples and/or
a second strategy that generates complete sequence data
on 10,000 or more case genomes. Significant findings
from either approach will implicate particular genes as
risk factors for schizophrenia, and these genes will hope-
fully converge on a limited number of pathways and will
thus provide valuable information about the genetic
etiology of schizophrenia. Either way, only very rarely
will an individual variant be determined to be causal in
an individual schizophrenia case, thus limiting the scope
for genetics in individual risk prediction.
The conclusions of this study must be tempered by
a number of considerations. First, we analyzed only coding
regions. It therefore remains possible that moderately rare
regulatory variants with relatively strong effect sizes
explain the majority of cases of schizophrenia. This would
seem to be an unlikely model on the basis of the promi-
nent role of coding variants in Mendelian disorders, but
it will be tested in the near future as variants identified
from whole-genome sequencing of individuals with
schizophrenia are investigated in larger data sets. One
example of a regulatory region that was not represented
in this study was that around the miRNA MIR137 (miR-
137), which was recently associated with schizophrenia
through a ‘‘mega-GWAS.’’26 It is also likely that some of
the variants that we included as likely to be functional
are in fact errors of reference-based mapping and that
other functional variants (e.g., nonsense mutations) were
excluded from the analysis as a result of mismapping.45
Second, our initial analysis included cases frommultiple
populations, including Finns and African Americans. If
rare schizophrenia-associated variants are population
specific, power would be reduced by the lack of focus on
a single ethnic or racial group. We know from previous
studies that different racial and ethnic groups share rare
CNVs,17 but this could be because they are in hypermu-
table regions. Thus, the same structural changes arise
multiple independent times, which is much less likely to
be the case for SNVs. Although we performed separate
analyses for samples of self-reported European and African
ancestry, we were not able to control for population struc-
ture within these groups. Stratification usually acts toan Journal of Human Genetics 91, 303–312, August 10, 2012 309
inflate test statistics, but the effect on power was expected
to be modest. Additionally, existing methods are not effec-
tive for the type of structure caused by rare variants.53 We
therefore employed the approach that was maximally
inclusive in this exploratory study and intended that any
variants that were supported in the second stage would
be further investigated in cohorts that are robust to the
effects of population stratification (e.g., in family-based
studies, as suggested in Mathieson et al.53). Finally, the
discovery sample comprised mostly people with
treatment-resistant schizophrenia; these individuals are
a special population representing about 30% of people
who meet the DSM-IV (Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition) criteria for schizo-
phrenia.54 The replication sample had a much smaller
percentage of treatment-resistant cases, so there remains
a possibility that real associated variants were not sup-
ported in the follow-up sample because they increase the
risk for treatment-resistant schizophrenia specifically, but
not for schizophrenia more generally.
Our findings will aid in the interpretation of future
small-scale sequencing studies. Here, we have investigated
almost all obviously functional variants in a set of 166
schizophrenia cases and have found no study-wide signif-
icant associations. Notably, the majority of nonprivate
variants that were exclusive to cases in the discovery
cohort were either seen in controls in the follow-up sample
(60%) or not seen in any further cases (23%). Thus, associ-
ations based on small-scale sequencing studies, however
biologically enticing, must be interpreted with caution
pending validation in larger follow-up studies.
If the majority of variants occur at a very low frequency,
there are a number of potential investigative strategies.
The most obvious and immediate strategy would be to
use gene-based NGS approaches for comprehensively
investigating candidate genes (e.g., from CNV studies or
GWASs) in large data sets, as described above. This
approach would allow us to accurately gauge how much
of the heritability of schizophrenia is explained by genes
that have already been identified. We can also take advan-
tage of the relatively small early sequencing data sets to
identify a small number of promising candidate rare vari-
ants, such as those that continue to be absent in controls
in the present study, for genotyping in larger data sets.
Although the majority of these candidates will turn out
to be false positives, potential insight into schizophrenia
etiology is worth the cost if even one is statistically proven.
Finally, rare variants can be investigated via family studies
through either segregation analyses in multiplex families
or the search for de novo or recessive variants in sporadic
cases. Although both of these approaches are likely to
produce multiple candidate variants per family, with
adequate control data sets and by the comparison of
multiple families in collaborative efforts, it should be
possible to identify either recurring variants or repeatedly
disrupted genes that will ultimately prove to contribute
to schizophrenia risk.310 The American Journal of Human Genetics 91, 303–312, August 1Supplemental Data
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